BHVNBiohaven Pharmaceutical Holding Company Ltd.

Regeneron Pharmaceuticals stock has delivered a 43.0% return over the past year, yet the broader valuation checks point to a more mixed picture rather than a clear bargain or obvious overpricing. With recent partnership activity and pipeline progress in the spotlight, investors are weighing how much of that is already reflected in the current US$840.84 share price. The 43.0% one year return signals that the market has already repriced Regeneron Pharmaceuticals positively. The key issue for...

Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron’s cemiplimab (Libtayo) in patients with solid tumors. BHV-1530’s novel topoisomerase I (TopoIx) payload generates immunogenic cell death and […]

Biohaven (BHVN) said Monday that a federal jury has awarded it $1 million in damages over an alleged